Skip to main content
Ester Calvo Fernández on Muck Rack

Ester Calvo Fernández

As seen in: Color Research & Application, Nature, El Diario, BioRxiv, Cell Press, Telecinco, Madrid Actual, La Tarde
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ester Calvo

Contact Ester Calvo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Acquired genetic and cell-state changes in IDH-mutant glioma progression

|
By Kevin Johnson, Avishay Spitzer, Frederick S. Varn, Masashi Nomura, Luciano Garofano, Tamrin Chowdhury, Anuja Lipsa, Linbin Zhang, Ester Calvo Fernández, Tanyeri Barak, Samirkumar B. Amin, Emre Kocakavuk, Dacheng Zhao, Fulvio D’Angelo, Simona Migliozzi, Lillian Bussema, Simon Gritsch, Sun Ha Paek, Franck Bielle, Alice Laurenge, Bertrand Mathon, Alberto Picca, Marc Sanson, Ann-Christin Hau, Frank Hertel, Kamil Grzyb, Zheng Zhao, Qianghu Wang, Tao Jiang, Julie Miller, Hiroaki Wakimoto, Daniel Cahill, Jennifer Moliterno, Murat Gunel, Beth Hermes, Nader Sanai, Anna Golebiewska, Simone P Niclou, Jason T. Huse, W. K. Alfred Yung, Anna Lasorella, Mario L. Suvà, Antonio Iavarone, Itay Tirosh, Roel G. W. Verhaak, A. Gulhan Ercan-Sencicek, Ayse Buket Peksen, C. Mircea S. Tesileanu, Hyo-Eun Moon
| Nature Verified
Abstract Gliomas with mutant isocitrate dehydrogenase (IDH) are malignant brain tumours that typically arise in early to mid-adulthood and nearly always recur following treatment1,2. However, the genetic and cellular-state changes that drive IDH-mutant glioma progression under treatment remain incompletely understood.
Open in Who Shared Issue with article?

Systematic design of combination therapy by targeting master regulators of coexisting diffuse midline glioma cell states

|
By Ester Calvo Fernández, Lorenzo Tomassoni, Xu Zhang, Junqiang Wang, Aleksandar Obradovic, Pasquale Laise, Aaron Griffin, Lukas Vlahos, Hanna E Minns, Diana Morales, Christian Simmons, Matthew Gallitto, Hong-Jian Wei, Timothy Martins, Pamela S Becker, John Crawford, Theophilos Tzaridis, Robert Wechsler-Reya, James Garvin, Robyn D. Gartrell, Luca Szalontay, Stergios Zacharoulis, Cheng-Chia Wu, Zhiguo Zhang, Andrea Califano, Jovana Pavisic
| Nature Verified
Abstract Intratumor heterogeneity fundamentally challenges cancer treatment, as coexisting, molecularly distinct cell states with non-overlapping drug sensitivities can drive therapeutic resistance. We establish and validate a generalizable, network-based framework to systematically identify combination therapies targeting complementary tumor cell states.
Open in Who Shared Issue with article?

A blueprint for local and distal invasion programs in glioblastoma

|
By Rony Chanoch-Myers, Toshiro Hara, Alissa C. Greenwald, Rouven Hoefflin, Lillian Bussema, Hannah Weisman, Edwin Nieblas-Bedolla, Zhibek Bekezhankyzy, Ester Calvo Fernández, Avishay Spitzer, Wajd N Al-Holou, Sandra Camelo-Piragua, Jinan Behnan, Hiroaki Wakimoto, Mario L. Suvà, Itay Tirosh, Jahnavi Gurramkonda, Alexander Jucht, Biella Chiara, Rossella Galli
| Nature Verified
Abstract Glioblastoma invasion into brain parenchyma presents significant challenges for treatment but remains poorly understood. In this study, we combine single-cell RNA sequencing, spatial transcriptomics, and multiplexed imaging of orthotopic xenograft models to investigate glioblastoma invasion. We first screen 20 patient-derived gliomasphere models for their distal (i.e., extending to the contralateral hemisphere) and local invasive potential in mice.
Open in Who Shared Issue with article?
See all 36 articles